R. Gervais

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)

Fabrice Barlési, R. Gervais, H. Léna et al. · Annals of Oncology · 2011 · 245 citations · Full text

Medicine, Gfpc 07-01, Bronchial Neoplasm +7

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Fabrice Barlési, Arnaud Scherpereel, R. Gervais et al. · Annals of Oncology · 2014 · 169 citations · Full text

Oncology, First-line Cisplatin–pemetrexed–bevacizumab, Phase Iii Trial +8

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

R. Rosell, R. Gervais, A. Vergnenègre et al. · Journal of Clinical Oncology · 2011 · 148 citations

Advanced Nsclc P, Medicine, Phase Iii +14

Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin

Jean-Louis Pujol, Jean-Luc Breton, R. Gervais et al. · Annals of Oncology · 2005 · 129 citations

Gemcitabine–docetaxel Versus Cisplatin–vinorelbine, Medicine, Anti-cancer Agent +8

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)

R. Gervais, A Ducoloné, Jean-Luc Breton et al. · Annals of Oncology · 2004 · 117 citations

Weekly Schedule, Phase Ii, Advanced Lung Disease +11